

# Prevalence of Thermophilic *Campylobacter* and their Antimicrobial Resistance Profile in Food Animals in Lare District, Nuer Zone, Gambella, Ethiopia

Abdulkhik Abamecha<sup>1\*</sup>, Getahun Assebe<sup>2</sup>, Belay Tafa<sup>3</sup>, and Beyene Wondafrash<sup>4</sup>

<sup>1</sup>Department of Biomedical Sciences, Faculty of Public Health and Medical Sciences, Mettu University, Mettu, Ethiopia

<sup>2</sup>Department of Animal Sciences, College of Agriculture and Natural Resource, Gambella University, Gambella, Ethiopia

<sup>3</sup>School of Medicine, Dire Dawa University, Dire Dawa, Ethiopia

<sup>4</sup>Department of Laboratory Sciences and Pathology, College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia

**Corresponding author:** Abdulkhik Abamecha, Department of Biomedical Sciences, Faculty of Public Health and Medical Sciences, Mettu University, Mettu, Ethiopia, **E-mail:** [abdulkhikabamecha@gmail.com](mailto:abdulkhikabamecha@gmail.com)

**Received date:** 26 October 2015; **Accepted date:** 23 Nov 2015; **Published date:** 28 Nov 2015.

**Citation:** Abamecha A, Assebe G, Tafa B, Wondafrash B (2015) Prevalence of Thermophilic *Campylobacter* and their Antimicrobial Resistance Profile in Food Animals in Lare District, Nuer Zone, Gambella, Ethiopia. *J Drug Res Dev* 1(2): doi <http://dx.doi.org/10.16966/2470-1009.108>

**Copyright:** © 2015 Abamecha A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

**Background:** *Campylobacters* are the most common food borne zoonotic pathogens isolated from stools of patients with gastroenteritis worldwide. Despite *Campylobacters* with resistance to antimicrobial agents have been reported worldwide, the situation seems to deteriorate more rapidly in developing countries, where there is widespread and uncontrolled use of antibiotics. The aim of this study was to isolate and identify *Campylobacter* species and determine their antimicrobial resistance patterns from various food animals.

**Methods:** A cross sectional study was conducted in Lare district, Nuer Zone from April 2014 to February 2015. Isolation and identification of *Campylobacter* species from feces of various food animals were performed using standard bacteriological procedures. Antimicrobial resistance tests were performed using Kirby-Bauer disk diffusion method. Data were cleaned and entered into a computer and statistical analysis was performed using SPSS version 20. Chi-square and Fisher's exact tests were used to test the differences between proportions, and *P* value less than 0.05 was considered statistically significant.

**Results:** Out of 368 fecal samples processed, the rate of recovery of *Campylobacters* was 208 (56.5%); of which 174 (83.7%) were found to be *C. jejuni*, 27 (12.9%) were *C. coli* and 7 (3.4%) were found to be *C. lari*. The overall antibiotic resistance profile showed that 46.6-82.2% of resistance was observed in *C. jejuni* and 0-29.6% of resistance was observed in *C. coli* isolates. The rate of multi-drug resistance was between 46.6-80.5% among *C. jejuni*. Multidrug resistant strains among *C. coli* were not observed.

**Conclusions:** The presence of drug resistant strains among the isolates revealed that humans are at risk from a variety of sources with potential for severe disease consequences. Therefore, the development of antibiotic-resistant strains needs better surveillance programs and monitoring of the use of antimicrobials in veterinary medicine in the area.

**Keywords:** *Campylobacter* species; Antibiotic resistance; Food animals; Lare district; Gambella; Ethiopia

## Background

*Campylobacters* are Gram negative, non-spore forming, slender, spiral to curved rod-shaped bacteria that are commonly present in the intestinal tracts of domestic and wild animals [1]. *Campylobacter* species are classified "thermophilic" since they grow between 37 and 42°C, but incapable of growth below 30°C (absence of cold shock protein genes which play a role in low-temperature adaptation), with an optimum temperature of 41.5°C [2]. It is the leading human diarrheal pathogen in both developed and developing countries. Annually, approximately 400 million documented cases occur worldwide, resulting mainly from contamination of poultry or other meats, raw milk, other milk products and surface water [3,4]. Due to under-reporting, true number of cases is estimated to be up to 10 times higher than the documented case numbers [4]. In the United States, *Campylobacters* are ranked fourth among top five pathogens in causing food borne infections and is estimated to cause more than 9.4 million cases of campylobacteriosis each year [5].

In developing countries, most of the infection is food borne primarily due to consumption of unpasteurized milk, contaminated water and meat

especially poultry meat, rather than human to human transfer [6]. Cross contamination of ready to eat foods during preparation by food handlers as well as direct contact with food animals have also been identified [7,8]. Species of *Campylobacter* responsible for food poisoning are *C. jejuni*, *C. coli*, *C. lari*, and *C. upsaliensis*. The most common species associated with human campylobacteriosis are *C. jejuni* and *C. coli*, which, together, cause around 95% of all *Campylobacter* infections [9,10].

*Campylobacter* causes an acute self-limited disease characterized by diarrhea, fever and abdominal cramps [11]. Extraintestinal manifestations are rare and may include meningitis, endocarditis, septic arthritis, osteomyelitis, and neonatal sepsis [6]. The most important post infectious complication of *C. jejuni* is Guillian Barre Syndrome (GBS) and Miller Fischer Syndrome which is an acute demyelinating disease of peripheral nervous system [12].

Treatment with antibiotics for uncomplicated campylobacter infection is rarely indicated. However, antimicrobial resistance to clinically important drugs used for treatment (especially macrolides and fluoroquinolones) is increasingly reported for *Campylobacters* [13]. There is evidence that

patients infected with antibiotic-resistant strains suffer worse outcomes (invasive illness or death) than those infected with sensitive strains [14]. There is growing scientific evidence that the use of antibiotics in food animals, particularly in developed countries, leads to the development of resistant pathogenic bacteria that can reach humans through the food chain [15-17]. This underlines the need to limit the use of antimicrobials in veterinary practice to limit the occurrence of resistance.

The risks to human health vary between the different animal species and different countries and depend on variations in food preparation and consumption patterns. A reduction of the overall *Campylobacter* spp. burden in the food chain will result in a reduction in the number of cases of disease [18]. The few reported studies of *Campylobacter* spp. as human enteric pathogens in Ethiopia showed isolation rates ranging from 13.6% to 16.7% [19-21] and 39.6% from apparently healthy food animals [22]. Several countries have reported the epidemiology of *Campylobacter* in different wild and domestic animals [23-26]. The absence of national surveillance program, limited routine culture availability for the isolation of *Campylobacter* species at clinical and research settings, and the need for selective media and unique growth atmosphere make it difficult to give an accurate picture of the burden of disease in Ethiopia. This fact indicates that *Campylobacter* as a zoonosis is not given appropriate weight and consideration. In Ethiopia epidemiological data about the prevalence and antimicrobial susceptibility patterns of *Campylobacter* spp. are restricted to strains from clinical samples isolated from children with gastroenteritis [19-21]. There is neither an official surveillance nor monitoring system for the presence of *Campylobacter* in animals, nor for the use of antimicrobials in veterinary medicine. Therefore, the objective of this study was to investigate the prevalence and antimicrobial resistance patterns of *Campylobacter* species from intestinal tracts of various food animals in Nuer zone, Gambella, Southwest Ethiopia.

## Methods

### Study area

Nuer Zone is one of the three zones of the Ethiopian Region of Gambella. This zone is bordered by South Sudan on the south, west and north, by Anuak Zone on the southeast. Livestock product is the primary source of food and income in the Zone.

### Study design

A cross sectional study was conducted at Lare district, Nuer zone from April 2014 to February 2015.

### Sample size determination and sample collection technique

A single population proportion formula was employed to determine sample size using prevalence rate of 39.6 % from previous study [22] at 5% level of significance giving a total size of 368. One hundred seventy seven (177) cattle, 97 chickens, 39 sheep and 55 goats from Lare district were included in the study. Approximately 1-5 grams of fecal samples were obtained using direct rectal retrieval or rectal swab systems. The samples were taken with a sterile cotton swab moistened in nutrient broth and placed in Carry-Blair Transport medium (Oxoid Ltd, Basingstoke, Hampshire, England), and transported overnight on ice packs to Jimma University Medical Microbiology Laboratory.

### Isolation and differentiation of *Campylobacter* species

The fecal samples/swabs were processed immediately upon arrival using aseptic techniques. The collected fecal samples/swabs were homogenized in Preston enrichment broth base containing *Campylobacter* selective supplement IV (HiMedia Laboratories, Mumbai, India) and 5% (v/v) defibrinated sheep blood. After inoculation at 42°C for 24 h under a microaerophilic atmosphere provided by gas generating sachets

containing 5% O<sub>2</sub>, 10% CO<sub>2</sub>, and 85% N<sub>2</sub> (*Campy-Gen*; Oxoid Ltd.), 0.1 mL of the enrichment broth was then streaked onto *Campylobacter* selective agar base (HiMedia Laboratories, Mumbai, India) supplemented with an antibiotic supplement for the selective isolation of *Campylobacter* species (HiMedia Laboratories, Mumbai, India) and 5% (v/v) defibrinated sheep blood and incubated at 42°C for 48 h under the same condition. Suspected *Campylobacter* colonies from each selective agar plate were subcultured and identification of a presumptive *Campylobacter* species was performed using standard bacteriological methods. For confirmation and differentiation of *Campylobacter* species, gram staining, production of catalase, oxidase, hippurate hydrolysis, and resistance to cephalothin and nalidixic acid were used [27-29].

### Antimicrobial susceptibility testing

Antimicrobial susceptibility tests were performed using Kirby-Bauer disk diffusion technique. Mullen-Hinton agar supplemented with 5% sheep blood was prepared. A 0.5 McFarland turbidity standard equivalent bacteria suspension for inoculation was prepared and inoculated. Antimicrobial disks were applied and the plate was incubated at microaerophilic atmospheric condition at 37°C for 48 hours. The following antimicrobials were used with their respective concentrations in parenthesis: ampicillin (AMP, 10 µg), chloramphenicol (C, 30 µg), erythromycin (E, 15 µg), clindamycin (DA, 2 µg), gentamicin (CN, 10 µg), ciprofloxacin (CIP, 5 µg), norfloxacin (NOR, 10 µg), tetracycline (TE, 30 µg), cephalothin (KF, 30 µg), and nalidixic acid (NA, 30 µg). All the discs were from Oxoid Ltd. Company, England, UK. After 48 hours of incubation, the inhibition zones were measured to the nearest millimeter using a graduated ruler. The diameters of inhibition zones were measured around the disks and interpreted on the bases of CLSI 2011 interpretive criteria for Enterobacteriaceae to classify as sensitive, intermediate, or resistant [30] as described by others [1,31]. *Campylobacter jejuni* (ATCC 700819), *Campylobacter coli* (ATCC 33559), *Staphylococcus aureus* (ATCC 25923), *Enterococcus faecalis* (ATCC 29212), *Pseudomonas aeruginosa* (ATCC 27853), and *E.coli* (ATCC 25922) were used as control strains.

### Statistical analysis

Data were cleaned and entered into a computer and statistical analysis was performed using SPSS version 20. The study findings were explained in tables. Chi-square and Fisher's exact tests were used to test the differences between proportions, and *P*-value less than 0.05 was considered statistically significant.

## Results

### Prevalence of *Campylobacter*

Three hundred sixty eight (368) fresh faecal samples/rectal/cloacal swab samples were analyzed in the study. The rate of recovery of *Campylobacter* was 56.5% (208 out of 368) for all food animals. The number and percentage of *Campylobacter* strains isolated from each food animals were: cattle, 64/15/6; chicken, 73/10/1; sheep, 11/2/0; and goat, 26/0/0 respectively. All isolates found in goats were *C. jejuni* (100%), (Table 1).

According to the statistical analysis, the percentage of *Campylobacter* strains isolated from different food animals were statistically significant (*p*-value <0.05%).

### Species distribution

Among the 208 thermophilic *Campylobacter* strains isolated from various food animals, 174 (83.7%) were found to be *C. jejuni*, 27(12.9%) were *C. coli* and 7 (3.4%) were found to be *C. lari*. The number of *C. jejuni*, *C. coli* and *C. lari* isolated per food animal species were: cattle, 64/15/6; chicken, 73/10/1; sheep, 11/2/0; and goat, 26/0/0 respectively. All isolates found in goat were *C. jejuni* (100%), (Table 1).

Food animals	Total number of samples tested	Isolation rate Number (%)	C.jejuni Number (%)	C.coli Number (%)	C.lari Number (%)
Cattle	177	85(48)	64(75.3)	15(17.6)	6(7.1)
Chicken	97	84(86.6)	73(86.9)	10(11.9)	1(1.2)
Sheep	39	13(39)	11(84.6)	2(15.4)	0
Goat	55	26(33.3)	26(100)	0	0

**Table 1:** Prevalence of *Campylobacter* species in feces/rectal swabs of 368 various food animals in Nuer zone, southwest, Ethiopia (April 2014 to February 2015)

### Antimicrobial resistance profile of *Campylobacter* isolates

The antimicrobial resistance profile of *C. jejuni* and *C. coli* strains from food animals are shown in (Table 2). The rate of resistance of *C. jejuni* showed; ampicillin, chloramphenicol, clindamycin, gentamicin, ciprofloxacin, norfloxacin, tetracycline, cephalotin, nalidixic acid and erythromycin were (46.6%), (61.5%), (54.6%), (50%), (80.5%), (64.9%), (82.2%), (100%), (3.8%) and (60.3%), respectively. The rate of resistance of *C. coli* showed; ciprofloxacin and cephalotin were (29.6%) and (100%), respectively. The rate of multiple resistances among *Campylobacter* spp is shown in (Table 3). According to the different antibiotic groups, the frequencies of multidrug resistant strain (non-susceptible to  $\geq 1$  agent in  $\geq 3$  antimicrobial categories) were between 46.6-80.5% among *C. jejuni*. The frequencies of multidrug resistant strain among *C. coli* were 0%. Cephalothin was not considered as a multidrug resistant variant property as most *Campylobacters* are inherently resistant to this agent.

### Discussion

The occurrence of human *Campylobacter* gastroenteritis has largely been attributed to the consumption of contaminated food of animal origin [6]. In the present study, the prevalence of *Campylobacter* spp. in cattle fecal samples was found to be 48%. Our finding was inconsistent with *Campylobacter* isolated from fecal samples collected from cattle that previously were 34% [32], 27.9% [33] and 23.4% [34]. These differences in the prevalence of cattle associated *Campylobacter* can be attributed to several factors, including isolation methods, sample size and geographical location [11]. Out of 85 tested isolates the prevalence of *C.jejuni* was 75.3% that was higher than 17.6% *C. coli* and 7.1 *C. lari*. Our results were in harmony with Nielsen et al. [35] who found 90.9% of the isolates from fecal samples of cattle were *Campylobacter jejuni* and 6.8% were *C. coli*, Cakmak and Erol [36] identified 40.4% *C. jejuni* and 4.1% *C. coli* in Turkey meat samples. Our study reveals that healthy cattle are considered as reservoir for a number of thermophilic *Campylobacter* species, highlighting the importance of non-poultry farms as possible sources of *Campylobacter* infection. The high prevalence of *C. jejuni* in cattle should be of special concern and care should be taken to limit its spread during milking, slaughtering and dressing.

The reported prevalence of *Campylobacter* bacteria in broiler flocks ranged between 35-57% in Europe [37] and 64-100% in Africa [26,38,39]. In this study, 86.6% isolation rate of thermophilic *campylobacter* is observed in chickens, which is higher than the findings from previous study in Ethiopia (68.1%) [22]. Among the isolates, *C.jejuni* predominantly found (86.9%) followed by *C. coli* (11.9%) and *C. lari* (1.2%) (Table 2). Similar results have also been reported in other countries indicating a higher prevalence of *C. jejuni* than *C. coli* in poultry farms [40].

These results indicated that chickens raised without sanitary attention may harbor thermophilic *Campylobacter* species, especially *C. jejuni*. One might consider this an important risk factor, since there is a correlation between the presence of these bacteria in poultry products and its concentration in the intestinal tract [41].

Antibiotics	Number (%) <i>C. jejuni</i> strains	Number (%) <i>C. coli</i> strains
Ampicillin	81(46.6)	0 (0)
Chloramphenicol	107(61.5)	0(0)
Clindamycin	95(54.6)	0(0)
Gentamicin	87(50)	0(0)
Ciprofloxacin	140(80.5)	8(29.6)
Norfloxacin	113(64.9)	0(0)
Tetracycline	144(82.2)	0(0)
Cephalothin	174(100)	27(100)
Nalidixic acid	8(3.8)	0(0)
Erythromycin	105(60.3)	0(0)

**Table 2:** Resistance to 10 antibiotics in 174 *C. jejuni* and 27 *C. coli* strains isolated from food animals in Nuer Zone, Gambella, southwest, Ethiopia(April 2014 to February 2015)

No. of Antibiotics	Resistance profile	Number (%) of MDR isolates	
		<i>C. jejuni</i> (n=174)	<i>C. coli</i> strains (n=27)
R3	AMP,CL,CM	81(46.6)	0
	CL,CM,GM	107(61.5)	0
	CM,GM,CIP	95(54.6)	0
	GM,CIP,TE	87(50)	0
	CIP,TE,NA	140(80.5)	0
R4	AMP,CL,CM,GM	81(46.6)	0
	CL,CM,GM,CIP	107(61.5)	0
R5	CM,GM,CIP,TE	95(54.6)	0
	AMP,CL,CM,GM,CIP	81(46.6)	0
	CL,CM,GM,CIP,TE	107(61.5)	0
R6	CM,GM,CIP,TE,NA	95(54.6)	0
	AMP,CL,CM,GM,CIP,TE	81(46.6)	0
	CM,GM,CIP,TE,NA,AMP	95(54.6)	0

**Table 3:** Multidrug-resistance patterns of *C. jejuni* and *C. coli* strains isolated from various food animals in Nuer Zone, Gambella, southwest, Ethiopia (April 2014 to February 2015)

MDR: non-susceptible to  $\geq 1$  agent in  $\geq 3$  antimicrobial categories

R3: Resistance to three antibiotics; R4: Resistance to four antibiotics; R5: Resistance to five antibiotics; R6: Resistance to six antibiotics; AMP: Ampicillin TE:Tetracycline; CIP: Ciprofloxacin; CL: Chlormphenicol; ERY: Erythromycin; GM: Gentamycin; CM: Clindamycin; NA: Nalidixic acid

The prevalence of *Campylobacter* spp. in feces of sheep investigated was 39% which is comparable to the isolate rates of 38% reported by kassa et al. [22]. However, the present finding was higher than the rates of 11.9% recorded by reported by Acik and Cetinkaya [42], and 10.6% by Chanyalew et al. [43]. Among the thermophilic *Campylobacter* species isolated 84.6% were *C. jejuni* and 15.4% were *C.coli*. This was in agreement with those findings reported by Kassa et al. [22], Salihu et al. [44], and Rahimi et al. [45]. This implies that *C. jejuni* is the most common *Campylobacter* species in sheep in Ethiopia.

In this study, 33.3% (26 out of 55) of the goats sampled were found to harbor *Campylobacter* isolates in their faeces. In a study done in Sokoto State, Nigeria, on 1312 faecal samples, over a period of 2 years, Salihu et al. [44] found 20% of the faecal samples to be positive for *Campylobacter*. This high prevalence of *Campylobacter* in goat is of serious concern in view of the high rate of consumption of goat meat and row goat milk in most African countries. *C. jejuni* is the main causative agent of food-borne gastroenteritis in humans and also causes a variety of diseases, such as



enteritis, abortion, septicaemia and mastitis in animals [46]. In this study, all isolates found in goat were *C. jejuni* (100%). This indicates that goats can be regarded as a potential reservoir for human campylobacteriosis.

Antibiotic resistance in *Campylobacter* is emerging globally and has already been described by several authors and recognized by the WHO, as a problem of public health importance [5,47,48]. *Campylobacter* species resistant to antibiotics (*C. jejuni*, and *C. coli*) can be transferred from different sources to humans. This situation, alarmingly, announces the need to perform antimicrobial sensitivity tests for *Campylobacter*s. Macrolids and fluoroquinolones are usually considered the drugs of choice for treatment of food-borne *Campylobacteriosis* [11,41,49]. Since *C.jejuni* and *C.coli* demonstrate different susceptibility profiles, it is important to differentiate *Campylobacter* at the species level, and to provide antimicrobial susceptibility data for each species, in order to monitor the trend of antimicrobial resistance among *Campylobacter* isolates and to ensure effective treatment of *Campylobacter* infections. In the present study, most of the isolates were found to be resistant to the fluoroquinolone class of antibiotics, out of 174 *C. jejuni* isolates, 140 (80.5%) were resistant to ciprofloxacin, and 113(64.9%) were resistant to Norfloxacin. On the other hand, out of 27 *C. coli* isolates, 8(29.6) were resistant to ciprofloxacin, but no resistant strain to Norfloxacin. The resistance to erythromycin was reported to be 105(60.3%) among *C. jejuni* and none among *C. coli* isolates. This finding is a cause of concern, because the drugs of choice for treatment of food-borne *Campylobacteriosis* especially *C.jejuni* totally abolished. In such instances, controlling the spread of these organisms becomes of paramount importance.

Alternative antibiotic in the treatment of *campylobacteriosis* showed high rate of resistance. Out of 174 *C. jejuni* isolates, resistance to Ampicillin was observed in 81(46.6%), 107(61.5) to Chloramphenicol, 95(54.6%) to Clindamycin, 50(87%) to Gentamicin, 144(82.2%) to Tetracycline, 174(100%) and 8(3.8%) to Nalidixic acid. All *Campylobacter* strains isolated in the current study were resistant to cephalothin as most of these species are inherently resistant to the drug.

Several investigators have reported the increasing incidence of human *C. jejuni* and *C. coli* infections in many parts of the world for the last decade with higher multidrug resistance [49-51]. Multidrug resistance has been observed in most of the *Campylobacter* isolates in the present study. Out of 174 *C. jejuni* isolates, 46.6-80.5% isolates were multidrug resistance *C. jejuni*. These findings are also in agreement with the observations of several other researchers [11,52,53].

## Conclusions

We can conclude from our study that thermophilic *campylobacters*, *C. jejuni* and *C. coli/C. lari* are very frequent among food animals in Nuer Zone, Ethiopia, suggesting possible risks of infection to people through consumption of contaminated animal products or by direct contact with infected animals. Since the available evidence shows that food animals constitute a major reservoir for these organisms, interruption of transmission to human beings from these sources should be given a high priority. Awareness of the necessity for hand washing after contact with animals and their products and the importance of proper cooking and handling of foods of animal origin are probably as important in preventing *C. jejuni/coli* infections. Pasteurization of milk, chlorination of water supplies and proper cooking of foods readily kill these organisms.

The presence of drug resistant strains among the isolates reveals that humans are at risk from a variety of sources with potential for severe health consequences, Therefore, the development of antibiotic-resistant strains, call for surveillance and monitoring the use of antimicrobials in veterinary medicine to detect emerging resistance and to prevent the spread of antibacterial-resistant *campylobacter* strains.

## Acknowledgements

The authors would like to acknowledge Gambella University and Mettu University for the financial support. They would also like to thank Gambella Agricultural and Rural Development Bureau and the *Lare district* officials for allowing them to undertake the study. Finally, the authors acknowledge Jimma University for allowing the Laboratory set up.

## Competing Interests

The authors have no financial or other conflict of interest to declare in relation to this manuscript.

## Authors' Contributions

Abdulkhikim Abamecha designed the study and carried out the laboratory works and analysis, and drafted the manuscript. Beyene Wonafrash, Getahun Assebe, and Belay Tafa participated in the design of the study and helped to draft the manuscript. All authors have read and approved to the final version of the manuscript.

## References

1. Samie A, Ramalivhana J, Igumbor EO, Obi CL (2007) Prevalence, haemolytic and haemagglutination activities and antibiotic susceptibility profiles of *Campylobacter* spp. Isolated from human diarrhoeal stools in Vhembe District, South Africa. *J Health Popul Nutr* 25: 406–413.
2. Levin RE (2007) *Campylobacter jejuni*: are view of its characteristics, pathogenicity, ecology, distribution, subspecies characterization and molecular methods of detection. *Food Biotechnol* 21: 271–347.
3. Girard MP, Steele D, Chaignat CL, Kiény MP (2006) A review of vaccine research and development. *Human Enteric Infection* 24: 2732–2750.
4. Gibreel A, Taylor D (2006) Macrolide resistance in *Campylobacter jejuni* and *Campylobacter coli*. *J Antimicrob Chemother* 58: 243–255.
5. CDC (2010) Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food—10 states, 2009. *MMWR Morb Mortal Wkly Rep* 59: 418–422.
6. Humphrey T, O'Brien S, Madsen M (2007) *Campylobacter*s as Zoonotic Pathogens: A Food Production Perspective. *Int J Food Microbiol* 117: 237–257.
7. Enokimoto M, Kubo M, Bozono Y, Mieno Y, Misawa N (2007) Enumeration and identification of *Campylobacter* species in the liver and bile of slaughtered cattle. *Int J Food Microbiol* 118: 259–263.
8. Zorman T, Heyndrickx M, Uzunović-Kamberović S, Smole Mozina S (2006) Genotyping of *Campylobacter coli* and *C. jejuni* from retail chicken meat and humans with campylobacteriosis in Slovenia and Bosnia and Herzegovina. *Int J Food Microbiol* 110: 24–33.
9. Debruyne L, Gevers D, Vandamme P (2008) Taxonomy of the Family *Campylobacteraceae*. In: *Campylobacter* Nachamkin I, Szymanski CM, Blaser MJ, 3<sup>rd</sup> Edition, American Society for Microbiology: Washington, DC, USA 3–26.
10. Lastovica AJ, Allos BM (2008) Clinical Significance of *Campylobacter* and Related Species other than *Campylobacter jejuni* and *Campylobacter coli*. In: *Campylobacter*, Szymanski CM, Blaser MJ, 3<sup>rd</sup> Edition, American Society for Microbiology: Washington, DC, USA 123–149.
11. Allos BM (2001) *Campylobacter jejuni* infections: update on emerging issues and trends. *Clin Infect Dis* 32: 1201–1206.
12. Yuki N (2001) Infectious Origins of, and Molecular Mimicry in, Guillain-Barré and Fisher syndromes. *Lancet Infect Dis* 1: 29–37.
13. Aarestrup FM, Engberg J (2001) Antimicrobial resistance of thermophiles *Campylobacter*. *Vet Res* 32: 311–321.

14. Helms M, Simonsen J, Olsen KE, Mølbak K (2005) Adverse health events associated with antimicrobial drug resistance in *Campylobacter* species: a registry based cohort study. *J Infect Dis* 191: 1050-1055.
15. Aarestrup FM (1999) Association between the consumption of antimicrobial agents in animal husbandry and the occurrence of resistance bacteria among food animals. *Int J Antimicrob Agents* 12: 279-285.
16. vanLooveren M, Daube G, De Zutter L, Dumont JM, Lammens C, et al. (2001) Antimicrobial susceptibilities of *Campylobacter* strains isolated from food animals in Belgium. *J Antimicrob Chemother* 48: 235-240.
17. Avrain L, Humbert F, L'Hospitalier R, Sanders P, Vernozy-Rozand C, et al. (2003) Antimicrobial resistance in *Campylobacter* from broilers: Association with production type and antimicrobial use. *Vet Microbiol* 96: 267-276.
18. Newell D, Fearnley C (2003) Sources of *Campylobacter* colonization in broiler chickens. *Appl Environ Microbiol* 69: 4343-4351.
19. Asrat D, Hathaway A, Ekwall E, (1999) Studies on enteric campylobacteriosis in Tikur Anbessa and Ethio-Swedish children's hospital, Addis Ababa, Ethiopia. *Ethiop Med J* 37: 71-84.
20. Gedlu E, Aseffa A (1996) *Campylobacter* enteritis among children in north-west Ethiopia: a 1-year prospective study. *Ann Trop Paediatr* 16: 207-212.
21. Tafa B, Sawunet T, Tassew H, Asrat D (2014) Isolation and Antimicrobial Susceptibility Patterns of *Campylobacter* Species among Diarrheic Children at Jimma, Ethiopia. *Int J Bacteriol* 19: 1-6.
22. Kassa T, Gebre-selassie S, Asrat D (2005) The prevalence of thermotolerant *Campylobacter* species in food animals in Jimma Zone, Southwest Ethiopia. *Ethiop J Health Dev* 19: 225-229.
23. Rosef O, Gondrosen B, Kapperud G, Underdal B (1983) Isolation and characterization of *Campylobacter jejuni* and *Campylobacter coli* from domestic and wild mammals in Norway. *Appl Environ Microbiol* 46: 855-859.
24. Cabrita J, Rodrigues J, Bragança F, Morgado C, Pires I, et al. (1992) Prevalence, biotypes, plasmid profile and antimicrobial resistance of *Campylobacter* isolated from wild and domestic animals from northeast Portugal. *J Appl Bacteriol* 73: 279-285.
25. Aquino MH, Pacheco AP, Ferreira MC, Tibana A (2002) Frequency of isolation and identification of thermophilic campylobacters from animals in Brazil. *Vet J* 164: 159-161.
26. Osano O, Arimi SM (1999) Retail poultry and beef as source of *Campylobacter jejuni*. *East Afr Med J* 76: 141-143.
27. Bolton FJ, Wareing DR, Skirrowand MB, Hutchinson DN (1992) Identification and biotyping of *Campylobacter*, In: *Identification Methods in Applied and Environmental Microbiology*, Eds. Board, G.R. D. Jones and F.A. Skinner. Society for Applied Microbiology, Technical Series 29, Blackwell Scientific Publications, Oxford 151-161.
28. Hendriksen RS, Agenaar J, Van Bergen M (2003) A Global Salmonella Surveillance and Laboratory Support Project of the World Health Organization, Laboratory Protocols, Level 2 Training Course, 5<sup>th</sup> Edition, Identification of thermotolerant *Campylobacter*.
29. Barros-Velázquez J, Jiménez A, Villa TG (1999) Isolation and typing methods for the epidemiologic investigation of thermotolerant *Campylobacter*s. *Int Microbiol* 2: 217-226.
30. CLSI document M100—S21 (2011) Performance Standards for Antimicrobial Disk Susceptibility Tests; Twenty-First Informational Supplement, Approved Standard M100-S21, Wayne, PA, USA.
31. Uaboi-Egbenni PO, Bessong PO, Samie A, Obi CL (2011) Prevalence and antimicrobial susceptibility profiles of *Campylobacter jejuni* and *coli* isolated from diarrheic and non-diarrheic goat faeces in Venda region, South Africa. *Afr J Biotechnol* 10: 14116-14124.
32. Hoar BR, Atwill ER, Elmi C, Farver TB (2001) An examination of risk factors associated with beef cattle shedding pathogens of potential zoonotic concern. *Epidemiol Infect* 127: 147-155.
33. Sato K, Bartlett PC, Kaneene JB, Downes FP (2004) Comparison of Prevalence and Antimicrobial Susceptibilities of *Campylobacter* spp. Isolates from Organic and Conventional Dairy Herds in Wisconsin. *Appl Environ Microbiol* 70: 1442-1447.
34. Gharst G, Hanson D, Kathariou S (2006) Effect of direct culture versus selective enrichment on the isolation of thermophilic *Campylobacter* from feces of mature cattle at harvest. *J Food Prot* 69: 1024-1027.
35. Nielsen EM, Engberg J, Madsen M (1997) Distribution of serotypes of *Campylobacter jejuni* and *C. coli* from Danish patients, poultry, cattle and swine. *FEMS Immunol Med Microbiol* 19: 47-56.
36. Cakmak O, Erol I (2012) Prevalence of thermophilic *Campylobacter* spp. in Turkey meat and antibiotic resistance of *C. jejuni* isolates. *J Food Safety* 32: 452-458.
37. van de Giessen AW1, Bloemberg BP, Ritmeester WS, Tilburg JJ (1996) Epidemiological study on risk factors and risk reducing measures for *Campylobacter* infections in Dutch broiler flocks. *Epidemiol Infect* 117: 245-250.
38. Kazwala RR, Collins JD, Hannan J, Crinion RA, O'Mahony H (1990) Factors responsible for the introduction and spread of *Campylobacter jejuni* infection in commercial poultry production. *Vet Rec* 126: 305-306.
39. Simango C, Rukure G (1991) Potential sources of *Campylobacter* species in the homes of farm workers in Zimbabwe. *J Trop Med Hyg* 94: 388-392.
40. Padungton P, Kaneene JB (2003) *Campylobacter* spp. Inhuman, chickens, pigs and their antimicrobial resistance. *J Vet Med Sci* 65: 161-170.
41. Blaser MJ, Taylor DN, Feldman RA (1983) Feldman, Epidemiology of *Campylobacter jejuni* infections. *Epidemiol Rev* 5: 157-176.
42. Açik MN, Cetinkaya B (2006) Heterogeneity of *Campylobacter jejuni* and *Campylobacter coli* strains from healthy sheep. *Vet Microbiol* 115: 370-375.
43. Chanyalew Y, Asrat D, Amavisit P, Loongyai W (2013) Prevalence and Antimicrobial Susceptibility of Thermophilic *Campylobacter* Isolated from Sheep at Debre Birhan, North-Shoa, Ethiopia. *Kasetsart J* 47: 551-560.
44. Salihu MD, Junaidu AU, Oboegbulem SI, Egwu GO (2009) Prevalence and biotypes of *Campylobacter* Species isolated from sheep in Sokoto State, Nigeria. *Int J Anim Vet Adv* 1: 6-9.
45. Rahimi E, Hamid KR, Saman S, Karim A, Manouchehr M, et al. (2010) Detection and identification of *Campylobacter* spp. from retail raw chicken, turkey, sheep and goat meat in Ahvas, Iran. *Afr J Microbiol Res* 4: 1620-1623.
46. Aydin F, Atabay HI, Akan M (2001) The isolation and characterization of *C. jejuni* subsp. *Jejuni* from domestic geese (Anseranser). *J Appl Microbiol* 90: 637-642.
47. World Health Organization / Department of Communicable Disease Surveillance and Response (2001) The increasing incidence of human campylobacteriosis. Report and Proceeding of a WHO Consultation of Experts.
48. Ethelberg S, Simonsen J, Gerner-Smidt P, Olsen KE, Mølbak K (2005) Spatial distribution and registry-based case-control analysis of *Campylobacter* infections in Denmark, 1991- 2001. *Am J Epidemiol* 162: 1008-1015.
49. Butzler JP (2004) *Campylobacter*, from obscurity to celebrity. *Clin Microbiol Infect* 10: 868- 876.

50. Hakanen AJ, Lehtopolku M, Siitonen A, Huovinen P, Kotilainen P (2003) Multidrug resistance in *Campylobacter jejuni* strains collected from Finnish patients during 1995–2000. *J Antimicrob Chemother* 52: 1035–1039.
51. McGill K, Cowley D, Moran L, Scates P, O'Leary A, et al. (2006) Antibiotic resistance of retail food and human *Campylobacter* isolates on the island of Ireland from 2001–2002. *Epidemiol Infect* 134: 1282-1291.
52. T Luangtongkum T, Jeon B, Han J, Plummer P, Logue CM, et al. (2009) Antibiotic resistance in *Campylobacter*: emergence, transmission and persistence. *Future Microbiol* 4: 189-200.
53. Suman MH (2013) Isolation, identification and characterization of *Campylobacter* species from broiler meat in Mymensingh. *J Agric Food Tech* 4: 1-59.